Pharmaceutical News

RSS

Reducing iron levels in blood plasma may protect brain from changes related to AD

Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.

11 Apr 2012

Avid Radiopharmaceuticals receives FDA approval for Amyvid to treat AD

The U.S. Food and Drug Administration today approved Amyvid (Florbetapir F 18 Injection) a drug for Positron Emission Tomography (PET) imaging of the brain in adults who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.

11 Apr 2012

Oxytocin may offer hope for male sexual dysfunction

The hormone oxytocin that is also called the “love hormone” since it plays a role in the bond between a mother and baby may also improve sexual function - at least in men with Asperger’s syndrome - according to a published case report.

10 Apr 2012

Soon a vaccine that targets 90% of all cancers

Results from the safety trial - on patients with blood cancer - found all had greater immunity to the disease after receiving the vaccine. Three of the seven patients who have completed the treatment are now free of the condition.

10 Apr 2012

Biovest seeks Health Canada approval of BiovaxID for follicular NHL

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that Biovest is seeking marketing approval in Canada for BiovaxID, its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system.

10 Apr 2012

Akorn launches generic Vancocin for treatment of CDAD

Akorn, Inc., a niche specialty pharmaceutical company, today announced that it has launched Vancomycin Hydrochloride USP 125mg and 250mg capsules, the generic version of ViroPharma's Vancocin, which is indicated for the treatment of Clostridium difficile-associated diarrhea.

10 Apr 2012

Study questions whether FDA too tough on online pharmacies

The Food and Drug Administration has warned people about the many dangers of buying medications from foreign pharmacies over the Internet. While some sites might offer high-quality medicines, there are plenty that sell bogus and potentially dangerous products. But a recent economic analysis suggests that while there's good reason for the safety warnings, the FDA's stance on the matter might go too far.

10 Apr 2012

Lee's Pharma licenses rights to commercialize PL2200 Aspirin in China

PLx Pharma Inc, a Houston based pharmaceutical company developing gastrointestinal (GI) safer drugs has licensed to Lee's Pharmaceutical Holdings Limited (Lee's Pharma) the rights to register and commercialize in China, Hong Kong and Macau the PL2200 Aspirin, a GI safer aspirin product currently in development in the US, for prevention of cardiovascular diseases. Cardiovascular is one of the focus areas of Lee's Pharma.

10 Apr 2012

Potential role of aspirin in reducing risk of cancer death

A new report by American Cancer Society scientists says new data showing aspirin's potential role in reducing the risk of cancer death bring us considerably closer to the time when cancer prevention can be included in clinical guidelines for the use of aspirin in preventative care.

10 Apr 2012

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

Study finds successful weight loss strategies for obese people

A third of Americans are now obese, and up to 70% of them are trying to lose weight. In a new study published in the American Journal of Preventive Medicine, researchers from Harvard Medical School and Beth Israel Deaconess Medical Center in Boston have found in a nationally representative sample that obese dieters who said they ate less fat, exercised more, and used prescription weight loss medications were more likely to lose weight.

10 Apr 2012

FDA grants Fast Track designation to EpiCept's AmiKet

EpiCept Corporation announced today that AmiKet (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration.

10 Apr 2012

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

Affymax, Inc. today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS (peginesatide) Injection.

10 Apr 2012

Mayo Clinic introduces Breast Cancer Genome Guided Therapy Study

The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors.

10 Apr 2012

RegeneRx wins four patents in Israel, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel.

10 Apr 2012

HDS signs LOI with PharmaLife to market Clotamin in Russia

Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC are pleased to announce that HDS has signed a Letter of Intent with PharmaLife for placement of Clotamin with leading pharmacies in the Russian Federation.

10 Apr 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

Prescriptions on the rise for strongest pain pills

High-strength painkillers known as opioids represent the most widely prescribed class of medications in the United States.

9 Apr 2012

Survey finds high rating for Heraeus iBOND Self Etch bonding agent

Heraeus Kulzer, LLC, the worldwide leader in dental esthetics, announced today that its iBOND Self Etch bonding agent received the maximum possible "5-plus" rating from THE DENTAL ADVISOR. The iBOND Self Etch bottle kit was evaluated by 26 consultants in 648 uses and received a very impressive 96% clinical rating.

9 Apr 2012

TherapeuticsMD introduces second prescription prenatal vitamin

TherapeuticsMD, Inc., parent company of vitaMedMD, LLC, a specialty pharmaceutical company, announced that on April 9, 2012 it launched its second prescription prenatal vitamin, vitaMedMD One Rx, following the successful launch of vitaMedMD Plus Rx last month.

9 Apr 2012